Trump’s H-1B Visa Crackdown Threatens Cutting-Edge U.S. Medicine
- Biotech executives warn of an impending ‘crisis of science’
- Foreigners key to research; shortages of Americans with skills
Trump Visa Crackdown Threatens Biotech
This article is for subscribers only.
From tiny startups to global giants, the companies that sustain the $324 billion U.S. biotech industry are increasingly alarmed as President Donald Trump considers following his controversial travel ban with restrictions on skilled foreign immigrants.
To crank out discoveries, U.S. biotech firms such as Amgen Inc. and Gilead Sciences Inc., as well as overseas companies with stateside operations, rely on the world’s best scientists and lower-level researchers with scarce expertise.